2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroup
2020
Clinical and genomic factors associated with seizures in meningiomas.
Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.Peer-Reviewed Original ResearchPreoperative seizuresPostoperative seizuresAtypical histologyMultivariate analysisWorse progression-free survivalGenomic subgroupsYale-New Haven HospitalAssociation of seizuresAntiepileptic drug useProgression-free survivalSeizure-free patientsGross total resectionExtent of resectionMultiple risk factorsNF2 mutationsNew Haven HospitalLogistic regression modelsPostoperative radiationSeizure freedomClinical courseSeizure presentationSomatic NF2 mutationsBrain invasionRecurrent tumorsRisk factors
2019
ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.Peer-Reviewed Original ResearchSerious adverse eventsAdverse eventsRecurrent glioblastomaOverall survivalOutcome measuresDevice-related serious adverse eventsMedian overall survivalProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureLong-term treatmentMulti-center studyAnti-cancer therapyProspective studyTreatment groupsFeasible treatmentPatientsBrain cancerInvestigator's choiceInvestigational deviceChemotherapyGlioblastomaMonthsTreatmentACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.Peer-Reviewed Original ResearchAdverse eventsOutcome measuresDevice-related serious adverse eventsSerious adverse eventsProgression-free survivalSecondary outcome measuresCessation of treatmentFurther prospective studiesPrimary outcome measureStandard of careMulti-center studyMild dysesthesiaSurgical debulkingOverall survivalProspective studyClinical utilityFeasible treatmentPatientsBrain cancerInvestigational deviceMonthsTreatmentGBMSurvivalDebulking
2018
ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancer